Skip to main content

Southwest Airlines Announces Upcoming Board of Directors Changes

Tipranks - Wed Feb 11, 4:02PM CST

Valentine's Day Sale - 70% Off

Southwest Airlines ( (LUV) ) has shared an update.

Southwest Airlines Co. announced that directors C. David Cush and Gregg A. Saretsky submitted their resignations from the company’s Board of Directors on February 9, 2026, with both resignations to take effect on February 23, 2026. The company emphasized that neither director’s departure resulted from any disagreement regarding Southwest’s operations, policies, or practices, suggesting a planned board transition rather than governance or strategic conflict.

The most recent analyst rating on (LUV) stock is a Buy with a $61.00 price target. To see the full list of analyst forecasts on Southwest Airlines stock, see the LUV Stock Forecast page.

Spark’s Take on LUV Stock

According to Spark, TipRanks’ AI Analyst, LUV is a Neutral.

The score is held back primarily by weak and volatile free cash flow and thin current margins despite improved revenue and balance-sheet deleveraging. Technicals are supportive with a strong uptrend, but an overbought RSI adds near-term risk. Valuation is a headwind due to a high P/E, partially offset by a constructive earnings call featuring strong 2026 EPS and RASM guidance.

To see Spark’s full report on LUV stock, click here.

More about Southwest Airlines

Southwest Airlines Co. operates in the commercial aviation industry as a major U.S. low-cost carrier, providing domestic and limited international air transportation services to leisure and business travelers. The company focuses on high-frequency, point-to-point routes and seeks to compete on fares, operational reliability, and customer service within the competitive airline market.

Average Trading Volume: 9,819,717

Technical Sentiment Signal: Buy

Current Market Cap: $26.66B

For an in-depth examination of LUV stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.